Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Public comment period · §2

Draft supplier evaluation rubric — submissions

The 10 submissions received, published in full with declared interests and secretariat responses.

Document identifier
CEI-CP-002/2
Series
Public comment period
Version
1.0
Published
22 Oct 2023
Last reviewed
22 Oct 2023
Next review
22 Oct 2024
Identifier
10.71829/cei.cp.2
Certainty
Not rated
Cycle
2023 Q3
Window
06 Aug 2023 – 20 Sep 2023
Status
Closed
Submissions
10

§2Submissions and responses

10 submissions were received. Each is published in full below with its declared interest, the secretariat response and the disposition. The Institute publishes submissions it did not accept in the same form as those it did.

Dr Wilhelmina Erlingsson, RN, MSc (Advanced Practice) Sleep and respiratory medicine service
DRAFT-SUPPLIER-RUB/002 received 07 Aug 2023

The same concept is given three different names in one document

The draft refers to the same quantity as a response rate, a responder proportion and a categorical outcome in different sections. The respondent, who works in health-technology assessment, states that a reader cannot tell whether the three refer to one thing or to three.

The respondent proposes that the glossary term be used at every occurrence and that the glossary entry be linked at first use in each section rather than only at first use in the document.

Declared interest. Holds a personal shareholding, below the Institute's materiality threshold, in a diversified fund with pharmaceutical sector exposure. No direct holding in any named company.
Secretariat responseAccepted26 Sep 2023

The secretariat accepts this submission. The variation was stylistic and its cost to the reader exceeds any benefit.

A single term is now used throughout for each defined concept, and the glossary entry is linked at first use within each section rather than once per document.

Dr Rurik Underhill-Okafor, PhD (Biostatistics) University department of medicinal chemistry
DRAFT-SUPPLIER-RUB/008 received 07 Aug 2023

A superseded version should remain reachable from the version that replaced it

The respondent states that the draft supersedes an earlier document and that a reader who cited the earlier version has no way to reach it from the new one, which makes it impossible to see what changed.

The respondent asks that every version carry a link both to what it supersedes and to what supersedes it.

Declared interest. Is a member of the Institute's external reviewer register but did not review the document under consultation.
Secretariat responseNoted, no amendment22 Oct 2023

The secretariat notes this submission. The corrections and versioning policy already requires bidirectional version links and every superseded document is retained at its own address.

No amendment arises. The requirement is stated in the corrections and versioning policy and the amendment log of this document links to the version it replaced. The respondent is correct that the link was absent from the draft page furnished for consultation, which was a defect of the consultation copy and not of the policy.

Xenia Nyquist-Obiora, MPharm, MRPharmS Academic nephrology unit
DRAFT-SUPPLIER-RUB/007 received 11 Aug 2023

The document should state what a reader ought to do

The draft assesses evidence and stops. The respondent, a practising clinician, states that a reader arriving at the document with a decision to make is left to convert an assessment into an action without help, and proposes that each document close with a recommendation.

The respondent argues that other evidence bodies issue recommendations and that declining to do so transfers the difficult part of the work to the reader.

Declared interest. Has received consultancy fees from a supplier named in the Institute's supplier assessment set within the preceding two years.
Secretariat responseNot accepted13 Oct 2023

The secretariat does not accept this submission, and records that the point is a reasonable one rather than a misunderstanding.

The Institute assesses evidence and does not issue recommendations, because a recommendation embeds values and a resource context that the Institute does not hold and cannot state. That constitutional limit is published on the methodology page and is not varied by consultation. The submission remains published in full.

Dr Adaeze Dunmore-Ekpo, MD, MSc Community pharmacy practice, doctoral candidate
DRAFT-SUPPLIER-RUB/001 received 14 Aug 2023

Scores are reported to a precision the underlying judgements do not support

The respondent states that scores are reported to one decimal place while the underlying criteria are judged on coarse ordinal scales, and that the precision is spurious.

The respondent proposes that scores be reported as whole numbers.

Declared interest. Employed by an analytical laboratory that performs contract testing for suppliers, including at least one supplier named in the Institute's assessment set.
Secretariat responseAccepted in part12 Oct 2023

The secretariat accepts this submission in part. Reported precision is reduced. Scores are not rounded to whole numbers, because the resulting ties would themselves be read as findings of equivalence.

Scores are now reported to the precision the criteria support, the criterion-level judgements are published alongside the total so that the derivation can be checked, and the dossier states that a difference smaller than the reported precision is not a difference.

Nkechi Larsson-Ekwueme, MSc, CChem Academic sports-medicine and anti-doping laboratory
DRAFT-SUPPLIER-RUB/010 received 20 Aug 2023

A rubric score will be read as a statement about product quality

The respondent states that the rubric scores documentation and analytical evidence, that this is stated in the methodology, and that a numeric score placed beside a supplier name will nevertheless be read as a quality rating by most readers who encounter it.

The respondent proposes that the statement of what the score measures travel with the score rather than sitting in the methodology.

Declared interest. No financial interest. Has published a systematic review reaching a different conclusion from the draft, which the respondent declares as a non-financial interest.
Secretariat responseAccepted20 Oct 2023

The secretariat accepts this submission. A caveat a reader must navigate to is a caveat that will not be read.

A standing statement that the score assesses evidence and documentation rather than product quality is now printed at the head of every dossier, adjacent to every score wherever it appears, and in the comparison table.

Vittoria Quintanilha, MSc (Epidemiology) Academic clinical pharmacology unit
DRAFT-SUPPLIER-RUB/009 received 26 Aug 2023

A dossier rests on a small number of documents and does not say how many

The respondent states that the dossiers do not record how many certificates, batches or determinations the assessment examined, so a reader cannot tell whether a judgement rests on one document or on twenty.

The respondent proposes that the evidence base of each dossier be stated.

Declared interest. Employed by a national competent authority. This submission is made in a personal capacity and does not represent the position of that authority.
Secretariat responseAccepted19 Oct 2023

The secretariat accepts this submission. An assessment that does not state its own evidence base asks to be taken on trust.

Every dossier now states the number and type of documents examined, the period they cover and the route by which they were obtained, and a criterion assessed from a single document is marked as such.

Dr Rosalind Grünbaum-Sowande, PhD (Bioanalysis) University department of hepatology
DRAFT-SUPPLIER-RUB/003 received 29 Aug 2023

Point estimates are given without an interval

Several estimates in the draft appear as single figures. The respondent states that a point estimate without an interval invites a precision the underlying data do not support, and that the effect is worst where the estimate is drawn from a small contributing set.

The respondent proposes that no point estimate appear anywhere in the document set without its interval, including in summary tables and in the abstract.

Declared interest. Has previously served as an investigator on a trial included in the evidence base under consultation. Received no personal payment; institutional payment was made to the trial site.
Secretariat responseAccepted in part05 Oct 2023

The secretariat accepts this submission in part. Intervals are added wherever the source reports one. The proposal is declined for figures the source published without an interval, because the Institute will not compute an interval a source did not report.

Every estimate now carries its interval where the source reported one, and where it did not, the estimate is annotated as reported without an interval rather than left to appear as a precise figure.

Ignatius Erlingsson, BPharm, PhD National pharmacovigilance centre
DRAFT-SUPPLIER-RUB/004 received 06 Sep 2023

Quantitative claims are reproduced without the method that produced them

Several figures in the draft are quoted from sources that determined them by different methods. A figure obtained by one determination and a figure obtained by another are not comparable, and the draft places them in the same sentence without distinguishing them.

The respondent, an analytical chemist, proposes that every quantitative claim carry the method that produced it at the point of use rather than in the reference.

Declared interest. Is a practising clinician who prescribes compounds in the class under assessment. No financial relationship with any manufacturer.
Secretariat responseAccepted19 Oct 2023

The secretariat accepts this submission. Placing two figures side by side is an implicit claim that they are the same kind of quantity, and in the cases identified they were not.

Every quantitative claim now carries the determination that produced it at the point of use, and figures obtained by non-comparable methods are no longer presented in the same row or sentence.

Dr Oisín Marchetti-Bassey, MD, MPH Primary-care research network
DRAFT-SUPPLIER-RUB/005 received 12 Sep 2023

The search date is not on the face of the document

The draft carries a publication date and a review date but not the date on which the evidence was last searched. Those are three different dates and only the third tells a reader how current the assessment is. A document published in one quarter may rest on a search run two quarters earlier, and nothing on the page allows that gap to be measured.

The respondent proposes that the search date be printed adjacent to every certainty rating rather than in the methods section, on the ground that a reader who acts on a rating is unlikely to have read the methods section first.

Declared interest. Has used a compound in the class under assessment under prescription. Declared at the Institute's request; the Institute regards a lived-experience declaration as an interest and not as a disqualification.
Secretariat responseAccepted05 Oct 2023

The secretariat accepts this submission. The distinction between publication, review and search dates is real and the draft did not make it visible where it mattered.

The search date is now printed adjacent to every certainty rating and is carried in the document metadata, so that the interval between the search and the reading is visible without reference to the methods section.

Dr Rurik Haverkamp-Diallo, PhD (Medicinal Chemistry) University department of public health · industry submission
DRAFT-SUPPLIER-RUB/006 received 19 Sep 2023

The document should not describe uses outside the approved indication

The submission is made on behalf of a marketing-authorisation holder. It states that the draft describes uses of the compound that fall outside the approved indication, that such uses are not supported by the sponsor, and that describing them may be read as legitimising them.

The sponsor asks that the sections concerned be removed, or in the alternative that they carry a prominent statement that the sponsor does not support such use.

Declared interest. Is an employee of a marketing-authorisation holder for a compound named in the draft. This submission is made on behalf of that company and is identified as an industry submission throughout.
Secretariat responseNot accepted13 Oct 2023

The secretariat does not accept this submission. The Institute records what is supplied and what is used, because a reader encountering a compound outside a regulated route is the reader most in need of an assessment of the evidence for it.

The sections remain. Every such section already states the regulatory status of the use described and states that the evidence for it is assessed separately from the evidence for the approved indication. The submission is published in full and identified as an industry submission.

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

  1. International Organization for Standardization. ISO/IEC 17025:2017 General Requirements for the Competence of Testing and Calibration Laboratories. ISO/IEC Standard 2017;3rd edition. identifier not held by the Institute

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.